Su­per­nus ex­pands its port­fo­lio of Parkin­son's drugs with a $400M+ buy­out

4 years ago
Financing
Deals

The End­points 100 gives a C-suite thumbs down on 'crip­pling' price pro­pos­als and Aduhelm. Plus: Is any­one go­ing to JP ...

4 years ago
Bioregnum
Special

C4 co-founder re­signs as Dana-Far­ber trustee in the wake of new con­flict of in­ter­est poli­cies — re­port

4 years ago
R&D

Flex­ion heads to the dis­count aisle for a $450M+ merg­er with Paci­ra

4 years ago
Deals

Idor­si­a's Fab­ry dis­ease pro­gram flops a PhI­II study, leav­ing its fu­ture un­clear

4 years ago
R&D

Covid-19 roundup: Mer­ck sub­mits mol­nupi­ravir for EUA; In­dia re­sumes vac­cine ex­ports af­ter Delta surge

4 years ago
Coronavirus

Af­ter fil­ing for au­tho­riza­tion of its Covid-19 an­ti­body as a pro­phy­lac­tic, As­traZeneca pulls out new da­ta in the ...

4 years ago
R&D
Coronavirus

Af­ter three decades and a sur­prise re­jec­tion, first treat­ment for ba­bies born with­out a thy­mus se­cures FDA ap­proval

4 years ago
Cell/Gene Tx
FDA+

Search­ing for the next 'big hairy goal,' Blue­Rock CEO Emile Nuwaysir jumps to in vi­vo cell ther­a­py start­up En­so­ma

4 years ago
People
Cell/Gene Tx

Lat­est news: An­oth­er Alzheimer's 'break­through'?; GSK de­camps from icon­ic HQ; Red light in off-the-shelf CAR-T; ...

4 years ago
Weekly

Lu­men lands an­oth­er DoD con­tract to treat Covid-re­lat­ed GI is­sues

4 years ago
Deals
Coronavirus

The FDA adds a failed Alzheimer's drug to the 'break­through' club now look­ing for a near-term OK

4 years ago
FDA+

Af­ter skep­ti­cism and tight vote at ad­comm, FDA ap­proves Chemo­Cen­tryx's rare dis­ease drug

4 years ago
FDA+

Mi­rati teams with Sanofi on PhI/II tri­al for KRAS treat­ment com­bo; Ab­b­Vie los­es in lat­est Hu­mi­ra biosim­i­lar ...

4 years ago
News Briefing

Re­lay un­rolls ear­ly da­ta for an­ti-FGFR drug it thinks stand alone in terms of safe­ty pro­file

4 years ago
R&D

New­ly re­vealed texts from ex-FDA leader Stephen Hahn of­fer be­hind-the-scene glimpse in­to Trump’s Covid scare

4 years ago
FDA+

Care about R&D strate­gies? Have we got a sum­mit for you

4 years ago
Bioregnum

Covid-19 roundup: Pfiz­er, BioN­Tech seek au­tho­riza­tion of vac­cine for 5- to 11-year-olds; Fin­land halts roll­out of ...

4 years ago
Coronavirus

An­oth­er three biotechs are set to de­but on Nas­daq as com­bined in­dus­try raise tops $14B

4 years ago
Financing

Flag­ship turns to No­var­tis HR gu­ru in lat­est ad­di­tion; David Grainger sad­dles up to new po­si­tion at Centes­sa while ...

4 years ago
Peer Review

FDA's an­timi­cro­bial ad­comm unan­i­mous­ly backs Takeda's drug for post-trans­plant cy­tomegalovirus

4 years ago
Pharma
FDA+

Al­lo­gene hit with FDA clin­i­cal hold af­ter a pa­tient ex­pe­ri­ences 'ab­nor­mal­i­ty' in CAR-T cells — shares ham­mered

4 years ago
R&D
FDA+

New Eng­land-based dis­trib­u­tor HP­NE looks to dou­ble its work­force to keep up with de­mand

4 years ago
Outsourcing
Manufacturing

BioCi­na com­pletes takeover of Pfiz­er-owned Aus­tralia plant; Cam­brex adds space at NC site for small mol­e­cules

4 years ago
Manufacturing
First page Previous page 629630631632633634635 Next page Last page
A service from the Financial Times